Skip to main content
Premium Trial:

Request an Annual Quote


Illumina's Jay Flatley tells the story of his 2011 meeting with Roche in a video from Biocom's Speaker Series posted by the San Diego Union-Tribune.

In 2011, Illumina's stock price fell from the $70-a-share to $60-a-share range to about $24 a share, and that, Flatley says, was the impetus for Roche to come calling.

"I got a call from the CEO of Roche and he said, 'We'd like to have a meeting with you and your chairman,'" he says in the video. "We did that at Bill Rastetter's house down at the beach. It lasted about 40 minutes. And about three minutes in he said, 'Well, we're going to acquire your company.' And I said, 'Really?'"

According to Flatley, Roche wanted to do it in a friendly manner and they discussed what the company had in mind. Illumina, though, rejected their overtures, and the takeover bid turned hostile. Initially, Illumina was offered $44.50 a share, which was then upped to $51 a share. Roche ended its bid some three months later.

In other videos from the talk, Flatley discusses the company's early days as well as his worries about keeping the company well positioned to stay in the lead five years and longer down the line.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.